Fidaxomicin for Initial Episode of <i>Clostridioides difficile</i> Infection Reduces Recurrence in Immunocompromised Hosts-a Large Retrospective Cohort Study.

ABSTRACT:

Introduction

Fidaxomicin is a narrow-spectrum, nonabsorbable antibiotic recommended as first-line therapy for nonfulminant Clostridioides difficile infection (CDI). While some studies suggest a reduction of recurrence for immunocompromised hosts (ICHs), the findings remain inconsistent and limited. We aimed to evaluate the clinical outcomes of fidaxomicin for a first CDI episode in ICHs within a large healthcare system.

Methods

We conducted a retrospective cohort study of Clalit Health Services adults with a first laboratory-confirmed CDI between January 2013 and December 2023. Patients with prior CDI were excluded. The primary outcome was a composite of recurrence, 90-day mortality, and colectomy, which were compared between the fidaxomicin and vancomycin groups. Sec

SUBMITTER: Atamna A 

PROVIDER: S-EPMC12719386 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature